Regulation S-P - SEC.gov
Requires registered broker-dealers, investment companies, and investment advisers to "adopt written policies and procedures that address administrative, technical, and physical safeguards for the protection of customer records and information."
sensitive customer information, a type of customer information. This is information that, either alone or in conjunction with any other information, could create a reasonably likely risk of substantial harm or inconvenience to an individual identified with the
SEC.gov | Standard Industrial Classification (SIC) Code List
SIC Code Office Industry Title; 100: Industrial Applications and Services: AGRICULTURAL PRODUCTION-CROPS: 200: Industrial Applications and Services: AGRICULTURAL PROD-LIVESTOCK & ANIMAL SPECIALTIES
Regulation S-P: Privacy of Consumer Financial Information and ...
May 7, 2023 · The Securities and Exchange Commission (“Commission” or “SEC”) is adopting rule amendments that will require brokers and dealers (or “broker-dealers”), investment companies, investment advisers registered with the Commission (“registered investment advisers”), funding portals, and transfer agents registered with the Commission or another …
SEC.gov
Sesen Bio is currently conducting the Phase 3 VISTA trial, designed to support the registration of Vicinium for the treatment of high-risk NMIBC in patients who have previously received a minimum of two courses of Bacillus Calmette-Guérin (BCG) and whose disease is …
zy-20211231 - SEC.gov
Dec 31, 2021 · • production microbe development, including organism specific HTP genomic engineering in such organisms as filamentous fungi, Corynebacterium, Escherichia coli, Chinese Hamster Ovary (CHO) cells and Bacillus sp.;
Document - SEC.gov
About the VISTA Clinical Trial The VISTA trial is an open-label, multicenter, single-arm Phase 3 clinical trial evaluating the efficacy and tolerability of Vicinium® as a monotherapy in patients with high-risk, bacillus Calmette-Guérin (BCG) unresponsive non …
8-K - SEC.gov
0000950170-25-036264.txt : 20250310 0000950170-25-036264.hdr.sgml : 20250310 20250310160740 accession number: 0000950170-25-036264 conformed submission type: 8-k public document count: 13 conformed period of report: 20250310 item information: results of operations and financial condition item information: financial statements and exhibits filed as of …
Document - SEC.gov
The following is a list of subsidiaries of the Company, doing business under the name stated.
rprx-20231108 - SEC.gov
Adstiladrin is approved for the treatment of adult patients with high-risk, Bacillus Calmette- Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.